Wales Medical Analysis Services Tenders & Contracts

Cardiff and Vale University Health Board intends to award a contract for the provision of outsourced inherited cancer genetic testing services to a single supplier.This service is critical to supporting the All Wales Medical Genomics Service (AWMGS), ensuring continued access to timely and accurate diagnostic testing across Wales. Ongoing capacity constraints within in-house laboratory services, combined with sustained clinical demand, require the continuation of outsourced provision to maintain turnaround times and support patient care pathways.The selected supplier is already embedded within the service and has demonstrated the capability and capacity to deliver the required testing to the necessary quality standards. Maintaining this arrangement ensures continuity of service and avoids disruption to established clinical pathways.Introducing an alternative supplier at this stage would present significant operational and clinical risks, including delays to patient diagnosis, disruption to workflows, and additional onboarding and validation requirements.Awarding to a sole supplier is therefore considered necessary to ensure continuity of critical services, protect patient safety, and support ongoing service delivery.

The transfer of medical reports to assist policing investigations

The transfer of medical reports to assist policing investigations

Cardiff and Vale University Health Board intends to award a contract for the provision of outsourced inherited cancer genetic testing services to a single supplier.This service is critical to supporting the All Wales Medical Genomics Service (AWMGS), ensuring continued access to timely and accurate diagnostic testing across Wales. Ongoing capacity constraints within in-house laboratory services, combined with sustained clinical demand, require the continuation of outsourced provision to maintain turnaround times and support patient care pathways.The selected supplier is already embedded within the service and has demonstrated the capability and capacity to deliver the required testing to the necessary quality standards. Maintaining this arrangement ensures continuity of service and avoids disruption to established clinical pathways.Introducing an alternative supplier at this stage would present significant operational and clinical risks, including delays to patient diagnosis, disruption to workflows, and additional onboarding and validation requirements.Awarding to a sole supplier is therefore considered necessary to ensure continuity of critical services, protect patient safety, and support ongoing service delivery.

Cardiff and Vale University Health Board intends to award a contract for the provision of outsourced inherited cancer genetic testing services to a single supplier. This service is critical to supporting the All Wales Medical Genomics Service (AWMGS), ensuring continued access to timely and accurate diagnostic testing across Wales. Ongoing capacity constraints within in-house laboratory services, combined with sustained clinical demand, require the continuation of outsourced provision to maintain turnaround times and support patient care pathways. The selected supplier is already embedded within the service and has demonstrated the capability and capacity to deliver the required testing to the necessary quality standards. Maintaining this arrangement ensures continuity of service and avoids disruption to established clinical pathways. Introducing an alternative supplier at this stage would present significant operational and clinical risks, including delays to patient diagnosis, disruption to workflows, and additional onboarding and validation requirements. Awarding to a sole supplier is therefore considered necessary to ensure continuity of critical services, protect patient safety, and support ongoing service delivery.

This notice is to inform the public of a direct award for the provision of inherited cancer genetic testing services. The service is essential for the timely and accurate diagnosis of hereditary cancer syndromes, supporting clinical decision-making and patient care across NHS Wales. The contract has been awarded to a specialist provider with proven expertise and capability in delivering high-quality genetic testing aligned with national genomic standards. The award ensures continuity of service, compliance with clinical governance, and supports the strategic objectives of Genomics Partnership Wales.

This notice is to inform the public of a direct award for the provision of inherited cancer genetic testing services. The service is essential for the timely and accurate diagnosis of hereditary cancer syndromes, supporting clinical decision-making and patient care across NHS Wales. The contract has been awarded to a specialist provider with proven expertise and capability in delivering high-quality genetic testing aligned with national genomic standards. The award ensures continuity of service, compliance with clinical governance, and supports the strategic objectives of Genomics Partnership Wales.